Incremental yield of genetic retesting in hypertrophic cardiomyopathy
Variant / mechanism
Variants in newly HCM-associated genes, deep intronic MYBPC3 variants, intermediate-effect variants and reclassifications in classic sarcomeric genes
Summary
This multicentre study (four centres) retested 508 patients with hypertrophic cardiomyopathy and a prior negative genetic test using an updated NGS panel, after a median interval of 6.6 years. Retesting identified 48 HCM-related variants in 46 patients (9%): 14 in newly HCM-associated genes, 3 in deep intronic MYBPC3 regions, 18 intermediate-effect variants and 13 in classic genes, 8 of them reclassified. In multivariable analysis, late gadolinium enhancement (OR 3.52), the Mayo HCM score and the Toronto HCM score independently predicted a positive retest. Yield reached 80% in patients combining late gadolinium enhancement with a Toronto score ≥ 13, and 50% with late gadolinium enhancement and a Mayo score ≥ 4.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
An old negative test in HCM is not final: nearly one patient in eleven changes status, and cardiac MRI combined with the Mayo and Toronto scores provides a simple rule for deciding who to retest first. Retesting here relies on an updated panel, but the logic applies to exome or genome reanalysis, where recent genes are already captured; the deep intronic MYBPC3 variants, however, are a reminder of the limits of the exome. The cohort is old (median 70 years), which leaves the benefit for family screening open.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 8/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime